Edition [exclusive] — S Gastrointestinal And Liver Disease 12th

(metabolic dysfunction-associated steatotic liver disease), formerly known as NAFLD. New Chapters

Reflecting the global medical consensus, the textbook officially updates its hepatology nomenclature. It replaces old terminology with , providing contemporary management pathways for what was previously known as NAFLD. 3. Brand New Clinical Chapters

12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease s gastrointestinal and liver disease 12th edition

: Highlights modern minimally invasive interventions, including Peroral Endoscopic Myotomy (POEM), endoscopic submucosal dissection (ESD), and the expanding role of therapeutic endoscopic ultrasound (EUS).

Hepatology continues to grow in complexity. The 12th edition offers robust updates on Non-Alcoholic Fatty Liver Disease (NAFLD) and its progressive counterpart, Non-Alcoholic Steatohepatitis (NASH), acknowledging the rising global prevalence of metabolic syndrome. The liver transplantation protocols are updated to reflect current organ allocation policies (MELD score evolution) and post-transplant immunosuppression strategies, providing a vital resource for hepatologists and surgeons alike. The 12th edition offers robust updates on Non-Alcoholic

The editors have successfully navigated the tension between print limitations and the vast expansion of medical knowledge. The inclusion of over 1,000 full-color illustrations and endoscopic images is not merely aesthetic but pedagogical, providing visual correlates for the pathological descriptions found in the text.

Cirrhosis, portal hypertension, and complications. Fatty Liver Disease: The rising epidemic of NASH and NAFLD. The inclusion of over 1

The 12th edition integrates the latest clinical trials, societal guidelines, and technological breakthroughs. Several key areas stand out: 1. The Expanding Role of the Gut Microbiome

The text is integrated with an online companion site (access code included with purchase) featuring: